GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atreca Inc (OTCPK:BCEL) » Definitions » Cash-to-Debt

Atreca (Atreca) Cash-to-Debt : 16.70 (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Atreca Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Atreca's cash to debt ratio for the quarter that ended in Sep. 2023 was 16.70.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Atreca could pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Atreca's Cash-to-Debt or its related term are showing as below:

BCEL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.62   Med: 2852.75   Max: 60021.25
Current: 16.7

During the past 6 years, Atreca's highest Cash to Debt Ratio was 60021.25. The lowest was 0.62. And the median was 2852.75.

BCEL's Cash-to-Debt is ranked better than
62.73% of 1540 companies
in the Biotechnology industry
Industry Median: 6.52 vs BCEL: 16.70

Atreca Cash-to-Debt Historical Data

The historical data trend for Atreca's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Atreca Cash-to-Debt Chart

Atreca Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash-to-Debt
Get a 7-Day Free Trial 1,145.04 3,256.93 60,021.25 No Debt 1.10

Atreca Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.33 1.10 0.89 0.62 16.70

Competitive Comparison of Atreca's Cash-to-Debt

For the Biotechnology subindustry, Atreca's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atreca's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atreca's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Atreca's Cash-to-Debt falls into.



Atreca Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Atreca's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Atreca's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Atreca  (OTCPK:BCEL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Atreca Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Atreca's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Atreca (Atreca) Business Description

Traded in Other Exchanges
Address
835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070
Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.
Executives
Felix Baker other: Former 10% Owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp other: Former 10% Owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc other: Former 10% Owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker other: Former 10% Owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Roger Richard Ruiz officer: VP of Finance C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Stephen E Gould officer: Chief Scientific Officer C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Herb Cross officer: Chief Financial Officer 3061 ZANKER RD, SAN JOSE CA 95134
Tito Serafini director, officer: Chief Strategy Officer C/O ATRECA, INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Phillips Courtney officer: General Counsel & Secretary ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Philippe C Bishop officer: Chief Medical Officer C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
John A Orwin director, officer: President & CEO C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Stacey Ma director C/O ATRECA, INC., 835 INDUSTRIAL RD., SUITE 400, SAN CARLOS CA 94070
Stephen R Brady director C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Norman Michael Greenberg officer: Chief Scientific Officer 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
William Hewitt Robinson director 500 SAGINAW DRIVE, REDWOOD CITY CA 94063